Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice

Viruses. 2021 Jul 22;13(8):1422. doi: 10.3390/v13081422.

Abstract

Herpes simplex virus type 1 (HSV-1) is a prevalent human pathogen primarily transmitted through skin-to-skin contact, especially on and around mucosal surfaces where there is contact with contaminated saliva during periods of viral shedding. It is estimated that 90% of adults worldwide have HSV-1 antibodies. Cutaneous HSV-1 infections are characterized by a sensation of tingling or numbness at the initial infection site followed by an eruption of vesicles and then painful ulcers with crusting. These symptoms can take ten days to several weeks to heal, leading to significant morbidity. Histologically, infections cause ballooning degeneration of keratinocytes and formation of multinucleated giant cells, ultimately resulting in a localized immune response. Commonly prescribed treatments against HSV-1 infections are nucleoside analogs, such as acyclovir (ACV). However, the emergence of ACV-resistant HSV (ACVR-HSV) clinical isolates has created an urgent need for the development of compounds to control symptoms of cutaneous infections. RLS-0071, also known as peptide inhibitor of complement C1 (PIC1), is a 15-amino-acid anti-inflammatory peptide that inhibits classical complement pathway activation and modulates neutrophil activation. It has been previously shown to aid in the healing of chronic diabetic wounds by inhibiting the excessive activation of complement component C1 and infiltration of leukocytes. Here, we report that treatment of cutaneous infections of HSV-1 and ACVR-HSV-1 in BALB/cJ mice with RLS-0071 significantly reduced the rate of mortality, decreased zosteriform spread, and enhanced the healing of the infection-associated lesions compared to control-treated animals. Therefore, RLS-0071 may work synergistically with other antiviral drugs to aid in wound healing of HSV-1 cutaneous infection and may potentially aid in rapid wound healing of other pathology not limited to HSV-1.

Keywords: PIC1; RLS-0071; acyclovir-resistance; anti-inflammatory; antiviral; complement; herpes simplex type 1; neutrophil; wound healing; zosteriform infection.

MeSH terms

  • Acyclovir / pharmacology
  • Animals
  • Antiviral Agents / pharmacology
  • Complement Inactivating Agents / pharmacology
  • Complement Inactivating Agents / therapeutic use*
  • Drug Resistance, Viral
  • Herpes Simplex / drug therapy*
  • Herpes Simplex / pathology
  • Herpes Simplex / virology
  • Herpesvirus 1, Human / drug effects*
  • Herpesvirus 1, Human / enzymology
  • Herpesvirus 1, Human / genetics
  • Mice
  • Mice, Inbred BALB C
  • Peptides / pharmacology
  • Peptides / therapeutic use*
  • Thymidine Kinase / genetics

Substances

  • Antiviral Agents
  • Complement Inactivating Agents
  • Peptides
  • RLS-0071
  • Thymidine Kinase
  • Acyclovir